Our findings demonstrate that an elevated serum IL-10/IL-6 ratio (≥2.30) at initial diagnosis serves as an independent predictor of SCNSL development and disease progression in DLBCL. The gene discussed is IL6; the disease is diffuse large B-cell lymphoma.